TheStreet Upgrades Adaptimmune Therapeutics PLC (ADAP) to “C”
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) was upgraded by research analysts at TheStreet from a “d” rating to a “c” rating in a research note issued to investors on Thursday.
Other equities analysts have also recently issued research reports about the stock. SunTrust Banks, Inc. restated a “buy” rating and issued a $10.00 price objective on shares of Adaptimmune Therapeutics PLC in a research report on Thursday, October 12th. Zacks Investment Research upgraded shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $9.75 price objective on the stock in a research report on Wednesday, October 4th. BidaskClub upgraded shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research report on Sunday, July 16th. Leerink Swann restated an “outperform” rating and issued a $15.00 price objective on shares of Adaptimmune Therapeutics PLC in a research report on Friday, September 8th. Finally, ValuEngine upgraded shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 20th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $11.58.
Adaptimmune Therapeutics PLC (NASDAQ ADAP) traded up $0.27 during mid-day trading on Thursday, hitting $8.44. 343,460 shares of the company’s stock were exchanged, compared to its average volume of 257,291.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.24). Adaptimmune Therapeutics PLC had a negative net margin of 138.46% and a negative return on equity of 27.99%. The firm had revenue of $3.52 million for the quarter, compared to analysts’ expectations of $5.43 million. analysts forecast that Adaptimmune Therapeutics PLC will post -0.82 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.watchlistnews.com/thestreet-upgrades-adaptimmune-therapeutics-plc-adap-to-c/1683728.html.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Alps Advisors Inc. increased its stake in shares of Adaptimmune Therapeutics PLC by 4.9% in the second quarter. Alps Advisors Inc. now owns 63,892 shares of the biotechnology company’s stock worth $287,000 after purchasing an additional 2,996 shares in the last quarter. KCG Holdings Inc. purchased a new stake in shares of Adaptimmune Therapeutics PLC in the first quarter worth $133,000. Virtu KCG Holdings LLC increased its stake in shares of Adaptimmune Therapeutics PLC by 108.0% in the second quarter. Virtu KCG Holdings LLC now owns 50,279 shares of the biotechnology company’s stock worth $226,000 after purchasing an additional 26,105 shares in the last quarter. Paloma Partners Management Co purchased a new position in Adaptimmune Therapeutics PLC during the first quarter valued at $165,000. Finally, OxFORD Asset Management LLP purchased a new position in Adaptimmune Therapeutics PLC during the second quarter valued at $156,000. 68.12% of the stock is owned by hedge funds and other institutional investors.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.